The interaction mechanism of mental disorders and diabetes and the current status of intervention_West China Medical Journal

Authors：

 WANG Hongming

President & Dean’s Office, the Fourth People’s Hospital of Chengdu, Chengdu, Sichuan 610036, P. R. China;

Corresponding?author：

WANG Hongming, Email: wanghongming2021@163.com

Keywords：

Mental disorders; Diabetes; Interaction; Interventions

DOI：

10.7507/1002-0179.202106210

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The interaction mechanism between mental disorders and diabetes is complex, involving genetics, endocrine metabolism, inflammation, oxidative stress and other aspects, which makes it difficult to treat patients with mental disorders complicated by diabetes. Such patients mostly use drugs and non-drug interventions to relieve symptoms of mental disorders and improve blood sugar levels, but the mechanism of mental disorders and diabetes needs to be systematically summarized and needs practical means to intervene. This article starts with the pathogenesis of diabetes and then describes the interaction mechanism of schizophrenia, bipolar disorder, depression and diabetes in detail. Finally, the intervention measures for patients with mental disorders complicated by diabetes are summarized, which aims to provide a reference for medical staff engaged in related work.

Citation： WANG Hongming. The interaction mechanism of mental disorders and diabetes and the current status of intervention. West China Medical Journal, 2021, 36(7): 846-853. doi: 10.7507/1002-0179.202106210 Copy

1.	Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
2.	孫洪敏. 精神障礙伴發糖尿病患者的護理措施研究及分析. 糖尿病新世界, 2018, 21(11): 167-168.
3.	張丹. 健康教育在糖尿病伴發精神障礙患者中的應用效果. 中國醫藥指南, 2020, 18(36): 210-211.
4.	Diabetes Canada Clinical Practice Guidelines Expert Committee, Robinson DJ, Coons M, et al. Diabetes and Mental Health. Can J Diabetes, 2018, 42(Suppl 1): S130-S141.
5.	American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
6.	Chellappan DK, Sivam NS, Teoh KX, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother, 2018, 108: 1188-1200.
7.	Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes, 2018, 19(3): 346-353.
8.	Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr, 2019, 13(1): 364-372.
9.	Bakay M, Pandey R, Grant SFA, et al. The genetic contribution to type 1 diabetes. Curr Diab Rep, 2019, 19(11): 116.
10.	Principi N, Berioli MG, Bianchini S, et al. Type 1 diabetes and viral infections: what is the relationship?. J Clin Virol, 2017, 96: 26-31.
11.	Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet, 2016, 387(10035): 2340-2348.
12.	Dedrick S, Sundaresh B, Huang Q, et al. The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis. Front Endocrinol (Lausanne), 2020, 11: 78.
13.	Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 2014, 383(9922): 1068-1083.
14.	Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med, 2014, 371(23): 2237-2238.
15.	Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
16.	Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science, 2016, 354(6308): 69-73.
17.	孟建鳳, 姜誠勇, 凌迎春, 等. 精神分裂癥合并糖尿病醫院感染及護理干預對策分析. 中華醫院感染學雜志, 2018, 28(9): 1417-1419.
18.	劉啟龍, 王妮娜. 精神分裂癥患者服用抗精神病藥導致糖尿病的臨床分析. 河北醫藥, 2019, 41(20): 3141-3144.
19.	王會秋, 李群, 徐桂娟, 等. 首發精神分裂癥患者康復治療現狀. 中國健康心理學雜志, 2018, 26(11): 1756-1761.
20.	魏亮. 糖尿病并發癥治療藥物的研究進展. 中國城鄉企業衛生, 2021, 36(4): 40-42.
21.	于婷. 慢性精神分裂癥合并糖尿病患者的認知功能研究. 山東: 青島大學, 2017: 16-44.
22.	薛瑩, 趙青楓, 林紹陳, 等. 精神分裂癥與糖尿病關系的研究進展. 臨床醫藥文獻電子雜志, 2017, 4(67): 13254-13256.
23.	Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One, 2016, 11(11): e0166429.
24.	Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand, 2015, 132(2): 144-157.
25.	Coclami T, Cross M. Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus. East Mediterr Health J, 2011, 17(10): 777-783.
26.	汪曉暉, 郭向晴, 鮑晨曦, 等. 精神分裂癥患者 5-羥色胺 2C 受體基因多態性與 2 型糖尿病共病的關聯研究. 臨床精神醫學雜志, 2017, 27(3): 153-156.
27.	Mamakou V, Hackinger S, Zengini E, et al. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. BMC Psychiatry, 2018, 18(1): 249.
28.	郭向晴, 趙靜, 易正輝, 等. 精神分裂癥并發 2 型糖尿病與五羥色胺 2C 受體基因多態性的關聯性. 復旦學報(醫學版), 2021, 48(1): 1-7.
29.	張昌, 馮志強, 楊宏亮, 等. 長期住院女性精神分裂癥患者 2 型糖尿病發生率及相關因素研究. 中國實用醫藥, 2018, 13(28): 32-34.
30.	Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry, 2016, 50(5): 488-494.
31.	Postolache TT, Del Bosque-Plata L, Jabbour S, et al. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet, 2019, 180(3): 186-203.
32.	王嘉欣. 中國漢族人群精神分裂癥和 2 型糖尿病共享易感基因及其致病機制研究. 長春: 吉林大學, 2015: 28-38.
33.	Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol, 2021, 24(5): 367-382.
34.	Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res, 2010, 123(2/3): 234-243.
35.	Lovestone S, Killick R, Di Forti M, et al. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci, 2007, 30(4): 142-149.
36.	Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry, 2019, 76(10): 1052-1062.
37.	梅希, 吳錦林. 抗精神病藥物誘導糖尿病的分子機制研究進展. 中國糖尿病雜志, 2018, 26(7): 608-612.
38.	隋國梁, 萬易, 劉佳. 探討利培酮對精神分裂癥合并糖尿病患者的療效及認知功能的影響. 中國衛生標準管理, 2017, 8(8): 75-76.
39.	徐勁節, Qi Dake, 崔東紅. 奧氮平致代謝紊亂和心血管疾病研究進展. 中國神經精神疾病雜志, 2016, 42(5): 303-306.
40.	余海玲, 徐英妹, 楊蘭. 精神分裂癥并發糖尿病相關因素分析. 醫學理論與實踐, 2019, 32(16): 2554-2556.
41.	蔡驊琳, 江沛, 李煥德, 等. 下丘腦-垂體-腎上腺軸與精神分裂癥的關系. 中國神經精神疾病雜志, 2013, 39(11): 688-691.
42.	蔣昕, 紀家武, 陳紅巖, 等. 精神分裂癥下丘腦-垂體-腎上腺軸功能研究. 臨床精神醫學雜志, 2008(5): 292-294.
43.	劉莉. 精神分裂癥合并糖尿病的護理體會. 糖尿病新世界, 2019, 22(5): 166-167.
44.	Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry, 2015, 2(5): 431-451.
45.	Miller JN, Black D. Bipolar disorder and suicide: a review. Curr Psychiatry Rep, 2020, 22(2): 6.
46.	Teixeira AL, Colpo GD, Fries GR, et al. Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother, 2019, 19(1): 67-81.
47.	Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris, 2013, 107(4): 278-285.
48.	Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the AESOP first-episode cohort. Schizophr Bull, 2015, 41(3): 664-673.
49.	Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol, 2021, 18(2): 136-145.
50.	Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med, 2019, 51(5/6): 281-293.
51.	Chien IC, Chang KC, Lin CH, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry, 2010, 32(6): 577-582.
52.	Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord, 2016, 4(1): 13.
53.	Choat HM, Martin A, Mick GJ, et al. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: trial design and methodology. Contemp Clin Trials, 2019, 82: 93-100.
54.	Grain R, Lally J, Stubbs B, et al. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: a systematic review, meta-analysis, and case series. Psychiatry Clin Neurosci, 2017, 71(10): 678-689.
55.	Steardo L Jr, de Filippis R, Carbone EA, et al. Sleep disturbance in bipolar disorder: neuroglia and circadian rhythms. Front Psychiatry, 2019, 10: 501.
56.	潘雨, 孫少俐. 睡眠障礙與老年 2 型糖尿病關系的研究進展. 中西醫結合心血管病電子雜志, 2019, 7(3): 18-19.
57.	唐倩. 中老年人夜間睡眠時間與 2 型糖尿病及胰島素抵抗的關系及其機制探討. 重慶: 重慶醫科大學, 2015: 12-18.
58.	Hajek T, McIntyre R, Alda M. Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry, 2016, 29(1): 1-6.
59.	Tannous J, Cao B, Stanley JA, et al. Altered neurochemistry in the anterior white matter of bipolar children and adolescents: a multivoxel ¹H MRS study. Mol Psychiatry, 2020: 10.
60.	Zhao X, Han Q, Gang X, et al. Altered brain metabolites in patients with diabetes mellitus and related complications-evidence from ¹H MRS study. Biosci Rep, 2018, 38(5): BSR20180660.
61.	Hajek T, Calkin C, Blagdon R, et al. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry, 2015, 77(3): 295-303.
62.	Nandi A, Yan LJ, Jana CK, et al. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cell Longev, 2019, 2019: 9613090.
63.	Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, et al. Oxidative stress parameters and antioxidants in patients with bipolar disorder: results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord, 2021, 23(2): 117-129.
64.	Bhattamisra SK, Siang TC, Rong CY, et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update. Curr Diabetes Rev, 2019, 15(5): 382-394.
65.	Yehuda R. Stress and glucocorticoid. Science, 1997, 275(5306): 1662-1663.
66.	Fitzgerald PJ. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton Autacoid Pharmacol, 2009, 29(4): 143-156.
67.	Lambert CG, Mazurie AJ, Lauve NR, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord, 2016, 18(3): 247-260.
68.	Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in japanese and american subjects. Nutrients, 2018, 10(8): 1011.
69.	Lin JR, Huang SH, Wu CH, et al. Valproic acid suppresses autoimmune recurrence and allograft rejection in islet transplantation through induction of the differentiation of regulatory t cells and can be used in cell therapy for type1 diabetes. Pharmaceuticals (Basel), 2021, 14(5): 475.
70.	Khan S, Jena G. Valproic acid improves glucose homeostasis by increasing beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J Biochem Mol Toxicol, 2016, 30(9): 438-446.
71.	王忠, 羅誠, 張躍坤, 等. 服用非經典抗精神病藥與雙相情感障礙患者代謝綜合征發生相關性分析. 心理月刊, 2020, 15(2): 70.
72.	Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 2020, 7(1): 64-77.
73.	Holt RIG. association between antipsychotic medication use and diabetes. Curr Diab Rep, 2019, 19(10): 96.
74.	Ohta Y, Kosaka Y, Kishimoto N, et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes, 2011, 60(12): 3208-3216.
75.	Nestsiarovich A, Kerner B, Mazurie AJ, et al. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology, 2020, 112: 104511.
76.	Kalra G, Gill S, Tang TS. Depression and diabetes distress in south asian adults living in low- and middle-income countries: a scoping review. Can J Diabetes, 2020, 44(6): 521-529.
77.	World Health Organization. Depression and other common mental disorders. (2017-01-03)[2021-6-22]. https://www.who.int/publications/i/item/depression-global-health-estimates.
78.	沈宛穎, 曾昱興, 李文豪, 等. 基于 GBD 大數據的中國抑郁負擔現狀和趨勢分析. 職業與健康, 2021, 37(8): 1087-1092.
79.	Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol, 2019, 56(6): 631-650.
80.	Wang F, Wang S, Zong QQ, et al. Prevalence of comorbid major depressive disorder in type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med, 2019, 36(8): 961-969.
81.	Alzoubi A, Abunaser R, Khassawneh A, et al. The bidirectional relationship between diabetes and depression: a literature review. Korean J Fam Med, 2018, 39(3): 137-146.
82.	Semenkovich K, Brown ME, Svrakic DM, et al. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs, 2015, 75(6): 577-587.
83.	Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun, 2020, 11(1): 5881.
84.	Pomytkin IA, Cline BH, Anthony DC, et al. Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: a reciprocal risk factor for depression and insulin resistance?. Behav Brain Res, 2015, 276: 111-117.
85.	Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol, 2016, 12(3): 133-143.
86.	何文麗, 陳巧珍. 內源性大麻素系統在抑郁障礙診治中的研究進展. 精神醫學雜志, 2021, 34(1): 79-83.
87.	Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev, 2014, 45: 46-62.
88.	陽璐, 陳俊, 方貽儒. 氧化應激指標在抑郁癥中的研究進展. 臨床精神醫學雜志, 2020, 30(3): 208-210.
89.	Yamada C, Kishimoto N, Urata N, et al. Relationship between serum antioxidative vitamin concentrations and type 2 diabetes in Japanese subjects. J Nutr Sci Vitaminol (Tokyo), 2020, 66(4): 289-295.
90.	Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun, 2018, 69: 28-34.
91.	Yu Z, Lin L, Jiang Y, et al. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol Neurobiol, 2019, 56(4): 2314-2327.
92.	Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology, 2017, 42(1): 193-215.
93.	Karabatsiakis A, B?ck C, Salinas-Manrique J, et al. Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry, 2014, 4(6): e397.
94.	Yuzefovych LV, Pastukh VM, Ruchko MV, et al. Plasma mitochondrial DNA is elevated in obese type 2 diabetes mellitus patients and correlates positively with insulin resistance. PLoS One, 2019, 14(10): e0222278.
95.	Wang YL, Koh WP, Yuan JM, et al. Plasma ferritin, C-reactive protein, and risk of incident type 2 diabetes in Singapore Chinese men and women. Diabetes Res Clin Pract, 2017, 128: 109-118.
96.	Passaro A, Vigna GB, Romani A, et al. Distribution of paraoxonase-1 (PON-1) and lipoprotein phospholipase A2 (Lp-PLA2) across lipoprotein subclasses in subjects with type 2 diabetes. Oxid Med Cell Longev, 2018, 2018: 1752940.
97.	Wu D, Wu C, Zhong Y. The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J Cell Mol Med, 2018, 22(9): 4283-4291.
98.	苑杰, 嚴辭, 李永秋, 等. 抗抑郁藥物長期治療的潛在風險性. 中國新藥與臨床雜志, 2016, 35(7): 464-468.
99.	湯智慧, 朱曼, 郭代紅. 1 例 2 型糖尿病患者使用抗抑郁藥物的藥學監護. 中國藥業, 2015, 24(10): 75-76.
100.	魏嘉欣. 利培酮聯合二甲雙胍治療精神分裂癥合并 2 型糖尿病患者的效果觀察. 實用糖尿病雜志, 2021, 17(1): 158-159.
101.	朱杰, 皇甫宇歡. 老年 2 型糖尿病伴發精神障礙抗精神病的臨床探討. 人人健康, 2018(12): 8.
102.	姜玉濤, 關勇. 阿立哌唑與富馬酸喹硫平聯用治療精神分裂癥的效果分析. 河北醫藥, 2019, 41(11): 1716-1718.
103.	何金珠. 齊拉西酮治療早期精神分裂癥伴糖尿病的研究. 中國衛生標準管理, 2020, 11(13): 67-68.
104.	陳孔樹, 吳祖美. 黃芪輔助治療伴糖尿病的精神分裂癥患者對血糖水平影響. 中外醫療, 2019, 38(35): 184-186.
105.	曹媛媛, 高淑英, 石川, 等. 疏肝益腎湯加減電針療法治療慢性精神分裂癥共病 2 型糖尿病認知功能障礙的療效觀察. 中國藥物與臨床, 2021, 21(6): 972-974.
106.	周琦. 針對性護理對精神分裂癥伴糖尿病患者血糖控制效果的影響. 當代護士(上旬刊), 2021, 28(5): 92-93.
107.	劉向群, 朱明文, 趙志君, 等. 精神分裂癥合并糖尿病患者膳食干預效果及其影響因素. 山東醫藥, 2019, 59(8): 69-72.
108.	宋珈瑩, 孫赫, 王會娟, 等. 運動療法對精神分裂癥合并糖尿病患者體重及血糖的影響. 中國當代醫藥, 2020, 27(16): 81-84.
109.	高淑英, 曹媛媛. 精神分裂癥合并 2 型糖尿病及伴發認知功能障礙患者中醫療法干預. 山西醫藥雜志, 2020, 49(14): 1790-1792.
110.	胡耀華, 林明欽, 鄒敏, 等. 敘事療法結合 PDCA 循環管理在精神分裂癥伴糖尿病患者中的應用. 中外醫學研究, 2020, 18(17): 168-170.
111.	甘建偉. 精神分裂癥合并糖尿病的護理干預效果及相關指標分析. 糖尿病新世界, 2021, 24(3): 109-111.
112.	McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res, 2006, 86(1/3): 36-44.
113.	Wong J, Mehta G. Efficacy of depression management in an integrated psychiatric-diabetes education clinic for comorbid depression and diabetes mellitus types 1 and 2. Can J Diabetes, 2020, 44(6): 455-460.
114.	國家衛生計生委合理用藥專家委員會, 中國藥師協會. 心力衰竭合理用藥指南(第 2 版). 中國醫學前沿雜志(電子版), 2019, 11(7): 1-78.
115.	陳曉燕. 帕羅西汀對 62 例抑郁癥合并 2 型糖尿病患者的臨床治療觀察探討. 糖尿病新世界, 2019, 22(24): 58-60.
116.	黨亞楠, 張偉, 惠晶, 等. 當代老齡化社會糖尿病伴焦慮、抑郁的現狀及應對措施. 中國社區醫師, 2018, 34(22): 9-10.
117.	Schnitzer K, Cather C, Thorndike AN, et al. Improved glycemic control in adults with serious mental illness and diabetes with a behavioral and educational intervention. Psychiatr Serv, 2020, 71(7): 730-733.
118.	林明芳. 臨床護理干預對老年精神障礙合并糖尿病患者生活質量的影響評價. 糖尿病新世界, 2020, 23(12): 166-168.
119.	Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry, 2016, 15(2): 166-174.
120.	朱大龍, 陸菊明. 《中國 2 型糖尿病防治指南(2020 年版)》編寫說明. 中華糖尿病雜志, 2021, 13(4): 312-314.
121.	中華醫學會精神醫學分會精神分裂癥協作組. 精神分裂癥患者代謝綜合征管理的中國專家共識. 中華精神科雜志, 2020, 53(1): 3-10.
122.	劉江洋, 繆海燕. 社區嚴重精神障礙患者共患糖尿病的調查及分析. 交通醫學, 2019, 33(3): 296-297.
123.	劉虎軍, 朱藝欣, 李海濤. 抗精神病藥導致糖尿病的相關危險因素 Logistic 回歸分析. 河北醫藥, 2020, 42(22): 3497-3499.

1. Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
2. 孫洪敏. 精神障礙伴發糖尿病患者的護理措施研究及分析. 糖尿病新世界, 2018, 21(11): 167-168.
3. 張丹. 健康教育在糖尿病伴發精神障礙患者中的應用效果. 中國醫藥指南, 2020, 18(36): 210-211.
4. Diabetes Canada Clinical Practice Guidelines Expert Committee, Robinson DJ, Coons M, et al. Diabetes and Mental Health. Can J Diabetes, 2018, 42(Suppl 1): S130-S141.
5. American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
6. Chellappan DK, Sivam NS, Teoh KX, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother, 2018, 108: 1188-1200.
7. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes, 2018, 19(3): 346-353.
8. Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr, 2019, 13(1): 364-372.
9. Bakay M, Pandey R, Grant SFA, et al. The genetic contribution to type 1 diabetes. Curr Diab Rep, 2019, 19(11): 116.
10. Principi N, Berioli MG, Bianchini S, et al. Type 1 diabetes and viral infections: what is the relationship?. J Clin Virol, 2017, 96: 26-31.
11. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet, 2016, 387(10035): 2340-2348.
12. Dedrick S, Sundaresh B, Huang Q, et al. The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis. Front Endocrinol (Lausanne), 2020, 11: 78.
13. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 2014, 383(9922): 1068-1083.
14. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med, 2014, 371(23): 2237-2238.
15. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
16. Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science, 2016, 354(6308): 69-73.
17. 孟建鳳, 姜誠勇, 凌迎春, 等. 精神分裂癥合并糖尿病醫院感染及護理干預對策分析. 中華醫院感染學雜志, 2018, 28(9): 1417-1419.
18. 劉啟龍, 王妮娜. 精神分裂癥患者服用抗精神病藥導致糖尿病的臨床分析. 河北醫藥, 2019, 41(20): 3141-3144.
19. 王會秋, 李群, 徐桂娟, 等. 首發精神分裂癥患者康復治療現狀. 中國健康心理學雜志, 2018, 26(11): 1756-1761.
20. 魏亮. 糖尿病并發癥治療藥物的研究進展. 中國城鄉企業衛生, 2021, 36(4): 40-42.
21. 于婷. 慢性精神分裂癥合并糖尿病患者的認知功能研究. 山東: 青島大學, 2017: 16-44.
22. 薛瑩, 趙青楓, 林紹陳, 等. 精神分裂癥與糖尿病關系的研究進展. 臨床醫藥文獻電子雜志, 2017, 4(67): 13254-13256.
23. Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One, 2016, 11(11): e0166429.
24. Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand, 2015, 132(2): 144-157.
25. Coclami T, Cross M. Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus. East Mediterr Health J, 2011, 17(10): 777-783.
26. 汪曉暉, 郭向晴, 鮑晨曦, 等. 精神分裂癥患者 5-羥色胺 2C 受體基因多態性與 2 型糖尿病共病的關聯研究. 臨床精神醫學雜志, 2017, 27(3): 153-156.
27. Mamakou V, Hackinger S, Zengini E, et al. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. BMC Psychiatry, 2018, 18(1): 249.
28. 郭向晴, 趙靜, 易正輝, 等. 精神分裂癥并發 2 型糖尿病與五羥色胺 2C 受體基因多態性的關聯性. 復旦學報(醫學版), 2021, 48(1): 1-7.
29. 張昌, 馮志強, 楊宏亮, 等. 長期住院女性精神分裂癥患者 2 型糖尿病發生率及相關因素研究. 中國實用醫藥, 2018, 13(28): 32-34.
30. Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry, 2016, 50(5): 488-494.
31. Postolache TT, Del Bosque-Plata L, Jabbour S, et al. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet, 2019, 180(3): 186-203.
32. 王嘉欣. 中國漢族人群精神分裂癥和 2 型糖尿病共享易感基因及其致病機制研究. 長春: 吉林大學, 2015: 28-38.
33. Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol, 2021, 24(5): 367-382.
34. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res, 2010, 123(2/3): 234-243.
35. Lovestone S, Killick R, Di Forti M, et al. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci, 2007, 30(4): 142-149.
36. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry, 2019, 76(10): 1052-1062.
37. 梅希, 吳錦林. 抗精神病藥物誘導糖尿病的分子機制研究進展. 中國糖尿病雜志, 2018, 26(7): 608-612.
38. 隋國梁, 萬易, 劉佳. 探討利培酮對精神分裂癥合并糖尿病患者的療效及認知功能的影響. 中國衛生標準管理, 2017, 8(8): 75-76.
39. 徐勁節, Qi Dake, 崔東紅. 奧氮平致代謝紊亂和心血管疾病研究進展. 中國神經精神疾病雜志, 2016, 42(5): 303-306.
40. 余海玲, 徐英妹, 楊蘭. 精神分裂癥并發糖尿病相關因素分析. 醫學理論與實踐, 2019, 32(16): 2554-2556.
41. 蔡驊琳, 江沛, 李煥德, 等. 下丘腦-垂體-腎上腺軸與精神分裂癥的關系. 中國神經精神疾病雜志, 2013, 39(11): 688-691.
42. 蔣昕, 紀家武, 陳紅巖, 等. 精神分裂癥下丘腦-垂體-腎上腺軸功能研究. 臨床精神醫學雜志, 2008(5): 292-294.
43. 劉莉. 精神分裂癥合并糖尿病的護理體會. 糖尿病新世界, 2019, 22(5): 166-167.
44. Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry, 2015, 2(5): 431-451.
45. Miller JN, Black D. Bipolar disorder and suicide: a review. Curr Psychiatry Rep, 2020, 22(2): 6.
46. Teixeira AL, Colpo GD, Fries GR, et al. Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother, 2019, 19(1): 67-81.
47. Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris, 2013, 107(4): 278-285.
48. Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the AESOP first-episode cohort. Schizophr Bull, 2015, 41(3): 664-673.
49. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol, 2021, 18(2): 136-145.
50. Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med, 2019, 51(5/6): 281-293.
51. Chien IC, Chang KC, Lin CH, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry, 2010, 32(6): 577-582.
52. Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord, 2016, 4(1): 13.
53. Choat HM, Martin A, Mick GJ, et al. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: trial design and methodology. Contemp Clin Trials, 2019, 82: 93-100.
54. Grain R, Lally J, Stubbs B, et al. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: a systematic review, meta-analysis, and case series. Psychiatry Clin Neurosci, 2017, 71(10): 678-689.
55. Steardo L Jr, de Filippis R, Carbone EA, et al. Sleep disturbance in bipolar disorder: neuroglia and circadian rhythms. Front Psychiatry, 2019, 10: 501.
56. 潘雨, 孫少俐. 睡眠障礙與老年 2 型糖尿病關系的研究進展. 中西醫結合心血管病電子雜志, 2019, 7(3): 18-19.
57. 唐倩. 中老年人夜間睡眠時間與 2 型糖尿病及胰島素抵抗的關系及其機制探討. 重慶: 重慶醫科大學, 2015: 12-18.
58. Hajek T, McIntyre R, Alda M. Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry, 2016, 29(1): 1-6.
59. Tannous J, Cao B, Stanley JA, et al. Altered neurochemistry in the anterior white matter of bipolar children and adolescents: a multivoxel ¹H MRS study. Mol Psychiatry, 2020: 10.
60. Zhao X, Han Q, Gang X, et al. Altered brain metabolites in patients with diabetes mellitus and related complications-evidence from ¹H MRS study. Biosci Rep, 2018, 38(5): BSR20180660.
61. Hajek T, Calkin C, Blagdon R, et al. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry, 2015, 77(3): 295-303.
62. Nandi A, Yan LJ, Jana CK, et al. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cell Longev, 2019, 2019: 9613090.
63. Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, et al. Oxidative stress parameters and antioxidants in patients with bipolar disorder: results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord, 2021, 23(2): 117-129.
64. Bhattamisra SK, Siang TC, Rong CY, et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update. Curr Diabetes Rev, 2019, 15(5): 382-394.
65. Yehuda R. Stress and glucocorticoid. Science, 1997, 275(5306): 1662-1663.
66. Fitzgerald PJ. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton Autacoid Pharmacol, 2009, 29(4): 143-156.
67. Lambert CG, Mazurie AJ, Lauve NR, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord, 2016, 18(3): 247-260.
68. Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in japanese and american subjects. Nutrients, 2018, 10(8): 1011.
69. Lin JR, Huang SH, Wu CH, et al. Valproic acid suppresses autoimmune recurrence and allograft rejection in islet transplantation through induction of the differentiation of regulatory t cells and can be used in cell therapy for type1 diabetes. Pharmaceuticals (Basel), 2021, 14(5): 475.
70. Khan S, Jena G. Valproic acid improves glucose homeostasis by increasing beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J Biochem Mol Toxicol, 2016, 30(9): 438-446.
71. 王忠, 羅誠, 張躍坤, 等. 服用非經典抗精神病藥與雙相情感障礙患者代謝綜合征發生相關性分析. 心理月刊, 2020, 15(2): 70.
72. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 2020, 7(1): 64-77.
73. Holt RIG. association between antipsychotic medication use and diabetes. Curr Diab Rep, 2019, 19(10): 96.
74. Ohta Y, Kosaka Y, Kishimoto N, et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes, 2011, 60(12): 3208-3216.
75. Nestsiarovich A, Kerner B, Mazurie AJ, et al. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology, 2020, 112: 104511.
76. Kalra G, Gill S, Tang TS. Depression and diabetes distress in south asian adults living in low- and middle-income countries: a scoping review. Can J Diabetes, 2020, 44(6): 521-529.
77. World Health Organization. Depression and other common mental disorders. (2017-01-03)[2021-6-22]. https://www.who.int/publications/i/item/depression-global-health-estimates.
78. 沈宛穎, 曾昱興, 李文豪, 等. 基于 GBD 大數據的中國抑郁負擔現狀和趨勢分析. 職業與健康, 2021, 37(8): 1087-1092.
79. Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol, 2019, 56(6): 631-650.
80. Wang F, Wang S, Zong QQ, et al. Prevalence of comorbid major depressive disorder in type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med, 2019, 36(8): 961-969.
81. Alzoubi A, Abunaser R, Khassawneh A, et al. The bidirectional relationship between diabetes and depression: a literature review. Korean J Fam Med, 2018, 39(3): 137-146.
82. Semenkovich K, Brown ME, Svrakic DM, et al. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs, 2015, 75(6): 577-587.
83. Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun, 2020, 11(1): 5881.
84. Pomytkin IA, Cline BH, Anthony DC, et al. Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: a reciprocal risk factor for depression and insulin resistance?. Behav Brain Res, 2015, 276: 111-117.
85. Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol, 2016, 12(3): 133-143.
86. 何文麗, 陳巧珍. 內源性大麻素系統在抑郁障礙診治中的研究進展. 精神醫學雜志, 2021, 34(1): 79-83.
87. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev, 2014, 45: 46-62.
88. 陽璐, 陳俊, 方貽儒. 氧化應激指標在抑郁癥中的研究進展. 臨床精神醫學雜志, 2020, 30(3): 208-210.
89. Yamada C, Kishimoto N, Urata N, et al. Relationship between serum antioxidative vitamin concentrations and type 2 diabetes in Japanese subjects. J Nutr Sci Vitaminol (Tokyo), 2020, 66(4): 289-295.
90. Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun, 2018, 69: 28-34.
91. Yu Z, Lin L, Jiang Y, et al. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol Neurobiol, 2019, 56(4): 2314-2327.
92. Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology, 2017, 42(1): 193-215.
93. Karabatsiakis A, B?ck C, Salinas-Manrique J, et al. Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry, 2014, 4(6): e397.
94. Yuzefovych LV, Pastukh VM, Ruchko MV, et al. Plasma mitochondrial DNA is elevated in obese type 2 diabetes mellitus patients and correlates positively with insulin resistance. PLoS One, 2019, 14(10): e0222278.
95. Wang YL, Koh WP, Yuan JM, et al. Plasma ferritin, C-reactive protein, and risk of incident type 2 diabetes in Singapore Chinese men and women. Diabetes Res Clin Pract, 2017, 128: 109-118.
96. Passaro A, Vigna GB, Romani A, et al. Distribution of paraoxonase-1 (PON-1) and lipoprotein phospholipase A2 (Lp-PLA2) across lipoprotein subclasses in subjects with type 2 diabetes. Oxid Med Cell Longev, 2018, 2018: 1752940.
97. Wu D, Wu C, Zhong Y. The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J Cell Mol Med, 2018, 22(9): 4283-4291.
98. 苑杰, 嚴辭, 李永秋, 等. 抗抑郁藥物長期治療的潛在風險性. 中國新藥與臨床雜志, 2016, 35(7): 464-468.
99. 湯智慧, 朱曼, 郭代紅. 1 例 2 型糖尿病患者使用抗抑郁藥物的藥學監護. 中國藥業, 2015, 24(10): 75-76.
100. 魏嘉欣. 利培酮聯合二甲雙胍治療精神分裂癥合并 2 型糖尿病患者的效果觀察. 實用糖尿病雜志, 2021, 17(1): 158-159.
101. 朱杰, 皇甫宇歡. 老年 2 型糖尿病伴發精神障礙抗精神病的臨床探討. 人人健康, 2018(12): 8.
102. 姜玉濤, 關勇. 阿立哌唑與富馬酸喹硫平聯用治療精神分裂癥的效果分析. 河北醫藥, 2019, 41(11): 1716-1718.
103. 何金珠. 齊拉西酮治療早期精神分裂癥伴糖尿病的研究. 中國衛生標準管理, 2020, 11(13): 67-68.
104. 陳孔樹, 吳祖美. 黃芪輔助治療伴糖尿病的精神分裂癥患者對血糖水平影響. 中外醫療, 2019, 38(35): 184-186.
105. 曹媛媛, 高淑英, 石川, 等. 疏肝益腎湯加減電針療法治療慢性精神分裂癥共病 2 型糖尿病認知功能障礙的療效觀察. 中國藥物與臨床, 2021, 21(6): 972-974.
106. 周琦. 針對性護理對精神分裂癥伴糖尿病患者血糖控制效果的影響. 當代護士(上旬刊), 2021, 28(5): 92-93.
107. 劉向群, 朱明文, 趙志君, 等. 精神分裂癥合并糖尿病患者膳食干預效果及其影響因素. 山東醫藥, 2019, 59(8): 69-72.
108. 宋珈瑩, 孫赫, 王會娟, 等. 運動療法對精神分裂癥合并糖尿病患者體重及血糖的影響. 中國當代醫藥, 2020, 27(16): 81-84.
109. 高淑英, 曹媛媛. 精神分裂癥合并 2 型糖尿病及伴發認知功能障礙患者中醫療法干預. 山西醫藥雜志, 2020, 49(14): 1790-1792.
110. 胡耀華, 林明欽, 鄒敏, 等. 敘事療法結合 PDCA 循環管理在精神分裂癥伴糖尿病患者中的應用. 中外醫學研究, 2020, 18(17): 168-170.
111. 甘建偉. 精神分裂癥合并糖尿病的護理干預效果及相關指標分析. 糖尿病新世界, 2021, 24(3): 109-111.
112. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res, 2006, 86(1/3): 36-44.
113. Wong J, Mehta G. Efficacy of depression management in an integrated psychiatric-diabetes education clinic for comorbid depression and diabetes mellitus types 1 and 2. Can J Diabetes, 2020, 44(6): 455-460.
114. 國家衛生計生委合理用藥專家委員會, 中國藥師協會. 心力衰竭合理用藥指南(第 2 版). 中國醫學前沿雜志(電子版), 2019, 11(7): 1-78.
115. 陳曉燕. 帕羅西汀對 62 例抑郁癥合并 2 型糖尿病患者的臨床治療觀察探討. 糖尿病新世界, 2019, 22(24): 58-60.
116. 黨亞楠, 張偉, 惠晶, 等. 當代老齡化社會糖尿病伴焦慮、抑郁的現狀及應對措施. 中國社區醫師, 2018, 34(22): 9-10.
117. Schnitzer K, Cather C, Thorndike AN, et al. Improved glycemic control in adults with serious mental illness and diabetes with a behavioral and educational intervention. Psychiatr Serv, 2020, 71(7): 730-733.
118. 林明芳. 臨床護理干預對老年精神障礙合并糖尿病患者生活質量的影響評價. 糖尿病新世界, 2020, 23(12): 166-168.
119. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry, 2016, 15(2): 166-174.
120. 朱大龍, 陸菊明. 《中國 2 型糖尿病防治指南(2020 年版)》編寫說明. 中華糖尿病雜志, 2021, 13(4): 312-314.
121. 中華醫學會精神醫學分會精神分裂癥協作組. 精神分裂癥患者代謝綜合征管理的中國專家共識. 中華精神科雜志, 2020, 53(1): 3-10.
122. 劉江洋, 繆海燕. 社區嚴重精神障礙患者共患糖尿病的調查及分析. 交通醫學, 2019, 33(3): 296-297.
123. 劉虎軍, 朱藝欣, 李海濤. 抗精神病藥導致糖尿病的相關危險因素 Logistic 回歸分析. 河北醫藥, 2020, 42(22): 3497-3499.

West China Medical Journal

The interaction mechanism of mental disorders and diabetes and the current status of intervention

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content